[go: up one dir, main page]

BR9706386A - Vitronectin receptor antagonists, their preparation and their use - Google Patents

Vitronectin receptor antagonists, their preparation and their use

Info

Publication number
BR9706386A
BR9706386A BR9706386-0A BR9706386A BR9706386A BR 9706386 A BR9706386 A BR 9706386A BR 9706386 A BR9706386 A BR 9706386A BR 9706386 A BR9706386 A BR 9706386A
Authority
BR
Brazil
Prior art keywords
preparation
receptor antagonists
vitronectin receptor
compounds
vitronectin
Prior art date
Application number
BR9706386-0A
Other languages
Portuguese (pt)
Inventor
Volkmar Wehner
Hans Ulrich Stilz
Anuschirwan Peyman
Karlheinz Scheunemann
Jean-Marie Ruxer
Denis Carniato
Jean-Michel Lefrancois
Thomas Richard Gadek
Robert Mcdowell
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of BR9706386A publication Critical patent/BR9706386A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"ANTAGONISTAS DO RECEPTOR DE VITRONECTINA, SUA PREPARAçãO E SEU USO". A presente invenção se refere a compostos de fórmula I, A-B-D-E-F-G (I) em que A, B, D, E, F e G têm os significados dados nas reivindicações da patente, à sua preparação e ao seu uso como medicamentos. Os compostos da invenção são usados como antagonistas do receptor da vitronectina e como inibidores da ressorção óssea."VITRONECTIN RECEPTOR ANTAGONISTS, PREPARATION, AND USE". The present invention relates to compounds of formula I, wherein A, B, D, E, F and G have the meanings given in the patent claims, their preparation and their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as bone resorption inhibitors.

BR9706386-0A 1996-12-20 1997-12-17 Vitronectin receptor antagonists, their preparation and their use BR9706386A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653645A DE19653645A1 (en) 1996-12-20 1996-12-20 Vitronectin receptor antagonists, their preparation and their use

Publications (1)

Publication Number Publication Date
BR9706386A true BR9706386A (en) 2003-04-22

Family

ID=7815760

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9706386-0A BR9706386A (en) 1996-12-20 1997-12-17 Vitronectin receptor antagonists, their preparation and their use

Country Status (19)

Country Link
US (1) US5990145A (en)
EP (1) EP0854145A3 (en)
JP (1) JPH10182617A (en)
KR (1) KR19980064419A (en)
CN (1) CN1200373A (en)
AR (1) AR010369A1 (en)
AU (1) AU729760B2 (en)
BR (1) BR9706386A (en)
CA (1) CA2225267A1 (en)
CZ (1) CZ411297A3 (en)
DE (1) DE19653645A1 (en)
HU (1) HUP9702509A3 (en)
ID (1) ID19245A (en)
IL (1) IL122643A0 (en)
NO (1) NO975975L (en)
NZ (1) NZ329429A (en)
PL (1) PL323968A1 (en)
TR (1) TR199701645A2 (en)
ZA (1) ZA9711315B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647380A1 (en) * 1996-11-15 1998-05-20 Hoechst Ag 5-ring heterocycles as inhibitors of leukocyte adhesion and VLA-4 antagonists
EP1140194A2 (en) 1998-12-23 2001-10-10 G.D. SEARLE & CO. Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
US6545032B1 (en) * 1999-09-17 2003-04-08 Torrey Pines Institute For Molecular Studies Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds
DE10028575A1 (en) 2000-06-14 2002-03-14 Basf Ag integrin
TWI258469B (en) * 2001-03-19 2006-07-21 Dainippon Pharmaceutical Co Aryl-substituted alicyclic compounds and pharmaceutical composition containing the same
EP1381384B1 (en) 2001-04-24 2011-05-25 Merck Patent GmbH COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
DK1443937T3 (en) 2001-11-13 2008-10-20 Ortho Mcneil Pharm Inc Substituted 1,4-benzodiazepines as well as their use in treating cancer
US7205315B2 (en) * 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
JP2009512443A (en) * 2005-10-20 2009-03-26 ザ スクリップス リサーチ インスチチュート Fc labeling for immunostaining and immunotargeting
AR056155A1 (en) * 2005-10-26 2007-09-19 Bristol Myers Squibb Co ANTAGONISTS OF NON-BASIC MELANINE CONCENTRATION HORMONE RECEIVER 1
ES2521679T3 (en) 2006-01-18 2014-11-13 Merck Patent Gmbh Specific therapy using integrin ligands for cancer treatment
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
CN101686680B (en) 2007-03-09 2015-12-09 伊沃泰克美国股份有限公司 Bicyclic heteroaryl compounds as P2X7 modulators and uses thereof
PE20091928A1 (en) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
KR20160147007A (en) 2014-05-30 2016-12-21 화이자 인코포레이티드 Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243326A (en) * 1991-06-28 1995-10-26 Smithkline Beecham Corp Benzodiazepine, benzazepine; benzothiazepine and benzoxazepine derivatives; pharmaceutical compositions
US5204350A (en) * 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) * 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
US5786373A (en) * 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5648368A (en) * 1992-12-01 1997-07-15 Merck & Co., Inc. Fibrinogen receptor antagonists
KR100318572B1 (en) * 1992-12-21 2002-04-22 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 Bicyclic fibrinogen antagonist
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
EP0760658B1 (en) * 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption
PL318199A1 (en) * 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
DE19516483A1 (en) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhesion receptor antagonists
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
TR199801255T2 (en) * 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronectin receptor antagonists.
BR9612381A (en) * 1995-12-29 1999-07-13 Smithkline Beecham Corp Vitronectin receptor antagonists
BR9612327A (en) * 1995-12-29 1999-07-13 Smithkline Beecham Corp Vitronectin receptor antagonists
EP0796855B1 (en) * 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitors of bone resorption and vitronectin receptor antagonists
DE19629817A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
DE19629816A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists

Also Published As

Publication number Publication date
IL122643A0 (en) 1998-08-16
ID19245A (en) 1998-06-28
MX9710389A (en) 1998-08-30
DE19653645A1 (en) 1998-06-25
ZA9711315B (en) 1998-06-22
CA2225267A1 (en) 1998-06-20
US5990145A (en) 1999-11-23
PL323968A1 (en) 1998-06-22
TR199701645A3 (en) 1998-07-21
CZ411297A3 (en) 1998-07-15
HUP9702509A2 (en) 1999-06-28
EP0854145A3 (en) 2000-03-22
AU729760B2 (en) 2001-02-08
HU9702509D0 (en) 1998-03-02
AR010369A1 (en) 2000-06-07
NZ329429A (en) 1999-05-28
NO975975L (en) 1998-06-22
TR199701645A2 (en) 1998-07-21
CN1200373A (en) 1998-12-02
NO975975D0 (en) 1997-12-19
HUP9702509A3 (en) 2001-04-28
JPH10182617A (en) 1998-07-07
EP0854145A2 (en) 1998-07-22
KR19980064419A (en) 1998-10-07
AU4846497A (en) 1998-06-25

Similar Documents

Publication Publication Date Title
BR9706386A (en) Vitronectin receptor antagonists, their preparation and their use
YU13396A (en) N- (3-BENZOFURANIL) UREA DERIVATIVES, PROCEDURES FOR OBTAINING THEM, THE COMPOSITIONS CONTAINING THEM, AND THEIR USE IN MEDICINES
SE8804629D0 (en) NEW THERAPEUTICALLY ACTIVE COMPOUNDS
BR9909565A (en) Bicyclic derivatives of hydroxamic acid
SE9504661D0 (en) New compounds
ES2102475T3 (en) NEW HETERO-CYCLIC ALKYL-AMIDES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
BR0009702A (en) Compounds or their salts, use of compounds or salts, and pharmaceutical formulations
BR9611175B1 (en) pharmaceutical compounds and compositions.
BR0016227A (en) Adamantane derivatives
BR0009703A (en) Compounds or salts, or compositions using them, and pharmaceutical formulations
BRPI0109200B8 (en) compounds and pharmaceutical compositions
ATE241990T1 (en) MEDICINAL COMPOSITIONS CONTAINING 3-BETA-HYDROXYLATED NATURAL STEROID DERIVATIVES AND THEIR USE
ES2157993T3 (en) BENZOILGUANIDINAS, ITS PREPARATION AND ITS USE IN MEDICINES.
DE3783356D1 (en) BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME.
AR004700A1 (en) 1ALFA, 26 DIHIDROXI-D-HOMO-VITAMIN D3, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A PROCEDURE FOR ITS PREPARATION AND USE OF THEM IN THE ELABORATION OF A MEDICINAL PRODUCT
BR9812492A (en) Compound, use of it, pharmaceutical formulation, and processes for the treatment of cardiovascular disease, for the treatment of vasoconstriction, and for the preparation of compounds
BG103219A (en) BENZAMIDINE DERIVATIVES AND USE THEREOF AS LTB4-ANTAGONISTIC ACTIVITY MEDICINES
ES2163735T3 (en) HETEROCICLIC BIARILE COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT CONTAIN THEM AND USES.
FI972434A0 (en) Lamotrigine-containing pharmaceutical composition
BR0309896A (en) Compounds, use in a compound, pharmaceutical composition, cosmetic composition, cosmetic use of a composition
CO4940448A1 (en) GLASS MODIFICATION OF A MEDICINAL SUBSTANCE
ES2089974A1 (en) USE OF THE DERIVATIVES OF 1- (4-) 4-ARIL (OR HETEROARIL) -1-PIPERAZINYL) -BUTYL) -1-H-AZOL FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISORDERS OF THE GASTRIC SECRETION.
LV10267A (en) A compound for the purpose of obtaining a compound compound
ES2105605T3 (en) TAQUIQUININE ANTAGONISTS, THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS.
DE69813263T2 (en) HYDRAZONO-BENZAZULEN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATE PRODUCTS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1833 DE 21/02/2006.